Table 3. Stratified analysis of the overall survival of four-lncRNA signature in the training set and testing set.

Variable	Training set			Testing set
	Number	HR	P	Number	HR	P
	(High/Low)	(95% CI)	value	(High/Low)	(95% CI)	value
Gender
Female	6/7	3.939 (0.409–37.96)	0.2	6/7	4.037 (0.365–44.68)	0.22
Male	45/45	3.603 (1.668–7.781)	0.0005*	38/49	2.405 (1.312–4.408)	0.0034*
Age
<60	45/35	3.536 (1.512–8.27)	0.0019*	34/47	2.412 (1.269–4.584)	0.0056*
≥60	6/17	4.253 (0.946–19.11)	0.059	10/9	7.153 (0.858–59.62)	0.069
ALT
≤50 U/L	27/34	2.985 (1.325–6.726)	0.0056*	22/32	2.479 (1.047–5.868)	0.033*
>50 U/L	24/18	10.87 (1.386–85.23)	0.0045*	22/24	2.358 (1.056–5.269)	0.032*
Main Tumor Size
≤5 cm	32/36	5.949 (1.963–18.02)	0.00036*	21/37	2.145 (0.993–4.637)	0.0523
>5 cm	18/16	2.213 (0.825–5.94)	0.11	23/19	2.5 (0.992–6.298)	0.0519
Multinodular
NO	39/47	4.157 (1.834–9.419)	0.00021*	30/44	3.017 (1.472–6.183)	0.0015*
YES	12/5	1.575 (0.316–7.857)	0.58	14/12	0.641 (0.231–1.777)	0.39
TNM stage
I+II	37/45	4.186 (1.633–10.73)	0.0012*	24/47	2.779 (1.337–5.778)	0.0043*
III	14/7	1.778 (0.555–5.693)	0.33	19/8	1.454 (0.503–4.206)	0.49
BCLC stage
0+A	36/47	4.728 (1.858–12.03)	0.00033*	26/43	3.238 (1.481–7.08)	0.0019*
B+C	15/5	0.879 (0.275–2.816)	0.83	17/12	0.630 (0.252–1.575)	0.32
AFP
≤300 ng/ml	21/33	3.944 (1.446–10.76)	0.0039*	17/35	4.625 (1.842–11.61)	0.00037*
>300 ng/ml	29/17	3.012 (1.004–9.033)	0.039*	27/21	1.438 (0.659–3.136)	0.36

Notes.

^*Statistically significant.

Abbreviations

BCLC stage

Barcelona Clinic Liver Cancer stage

Multinodular

whether the tumor has multiple nodules

HR

hazard ratio

95% CI

95% confidence interval